Lakewood-Amedex reports Nu-3 activity against drug-resistant bacteria in laboratory study
LABT•Lakewood-Amedex said laboratory findings showed Nu-3 had rapid activity against drug-resistant bacteria and low potential for resistance development. The company will present the research at IDWeek 2026 and expects topline results from its Phase 2a trial in the first quarter of 2027.
1. Research and trial plans
Lakewood-Amedex Biotherapeutics will present Nu-3 antimicrobial research at IDWeek 2026 on October 22, 2026. Laboratory findings showed rapid activity against resistant bacteria, with low potential for resistance development. Nu-3 is undergoing a Phase 2a trial as a topical treatment for mildly infected diabetic foot ulcers, with topline results expected in the first quarter of 2027.
